Results 1 to 10 of about 425,698 (387)
J Infect Dis, 2021 Abstract Hepatitis B is caused by the hepatitis B virus (HBV), which infects the liver and may lead to chronic liver disease, including cirrhosis and hepatocellular carcinoma. HBV represents a worldwide public health problem, causing major morbidity and mortality.
Pattyn J +3 more
europepmc +6 more sources
The Immunogenicity of the Influenza, Pneumococcal, and Hepatitis B Vaccines in Patients With Inflammatory Bowel Disease Treated With Vedolizumab. [PDF]
Crohns Colitis 360, 2020 Background Patients with inflammatory bowel disease (IBD) have an elevated risk for infection which is further increased by immunosuppressive medications.
Harrington JE +4 more
europepmc +2 more sources
Journal of Hepatology, 2003 Yeast-derived hepatitis B vaccines, containing the small HBV envelope protein SHBAg, are immunogenic, safe and cost-effective in prevention of hepatitis B virus infection in neonates, children and adults. Newly developed pre-S/S hepatitis B vaccines may play a role in inducing fast and augmented seroconversion rates in special risk groups.
D. Shouval
openaire +3 more sources
Booster Vaccination Against Invasive Pneumococcal Disease and Hepatitis B in Previously Vaccinated Solid Organ Transplant Recipients Without Seroprotection [PDF]
VaccinesBackground: Despite pre-transplantation vaccination against invasive pneumococcal disease (IPD) and hepatitis B virus (HBV), most solid organ transplant (SOT) recipients are without post-transplantation seroprotection against IPD and HBV.
Julie Sejerøe-Olsen +9 more
doaj +2 more sources
HBV Vaccines: Advances and Development
Vaccines, 2023 Hepatitis B virus (HBV) infection is a global public health problem that is closely related to liver cirrhosis and hepatocellular carcinoma (HCC). The prevalence of acute and chronic HBV infection, liver cirrhosis, and HCC has significantly decreased as ...
Faisal Mahmood +9 more
doaj +1 more source
Asian Journal of Medical Sciences, 2023 Background: Hepatitis B virus (HBV) infection affects more than 2 billion individuals globally HBV. The chance of dying from liver cirrhosis, acute fulminant liver disease, or hepatocellular carcinoma (HCC) is present in 240 million of these chronic HBV ...
Ramesh Thanikachalam +2 more
doaj +1 more source
Pediatric Discovery, 2023 Our aim is an achievement of a 100 percent vaccination rate without toxic vaccine effects. We did a comprehensive literature review on aluminum neurotoxicity and early neonatal hepatitis B vaccination.
Aleksandar Cirovic +3 more
doaj +1 more source
EVALUATION OF VACCINATION RESPONSE IN CHILDREN AFTER TREATMENT FOR ACUTE LEUKEMIA
Hematology, Transfusion and Cell Therapy, 2021 Objective: Our study aims to evaluate the patients’ immunity regarding childhood vaccination after leukemia treatment and determine the vaccines that require additional doses. Methodology: Sixty-six patients who were followed up with the diagnosis of ALL
Elif KILIC KONTE +4 more
doaj +1 more source
METHODS FOR ASSESSMENT OF THE SPECIFIC ACTIVITY OF DRUGS FOR PREVENTION OF HEPATITIS B
Вопросы вирусологии, 2017 The immunologic activity (specific activity) is one of the main indicators of quality of vaccines for prophylaxis of hepatitis B, along with their safety.
E. L. Postnova +3 more
doaj +1 more source
A Pre-Clinical Safety Evaluation of SBP (HBsAg-Binding Protein) Adjuvant for Hepatitis B Vaccine. [PDF]
PLoS ONE, 2017 Although adjuvants are a common component of many vaccines, there are few adjuvants licensed for use in humans due to concerns about their toxic effects.
Jingbo Wang +6 more
doaj +1 more source